Neonatal vaccination with 'universal strength' BCG vaccine

Area of Science:

• Immunology
• Pediatrics
• Vaccinology

Background:

• Tuberculosis remains a significant global health threat, particularly for infants.
• BCG vaccination is the primary method for preventing severe forms of childhood tuberculosis.
• Evaluating BCG vaccine efficacy and safety in neonates is crucial for public health strategies.

Purpose of the Study:

• To assess the immunogenicity and safety of the 'Universal strength' BCG vaccine in neonates.
• To determine the Mantoux conversion rate and evaluate local reactions post-vaccination.

Main Methods:

• Administered 'Universal strength' BCG vaccine to 219 neonates.
• Performed Mantoux testing (5 Tu PPD-S) on 159 infants at 2 months.
• Measured BCG scar size and documented local skin reactions.

Main Results:

• Achieved a satisfactory Mantoux tuberculin skin test conversion rate exceeding 90%.
• Observed local lesion discharge in 30% of infants, which resolved within a few days.
• The BCG vaccine was generally well-tolerated and acceptable in the neonatal population.

Conclusions:

• The 'Universal strength' BCG vaccine is immunogenic and safe for neonatal administration.
• High conversion rates suggest effective protection against tuberculosis.
• The vaccine's tolerability supports its widespread use in newborns for tuberculosis prevention.